HOPE
The Hub at Oxford for Psychedelic Ethics (HOPE) is a new interdisciplinary programme, which aims to develop sustainable frameworks for psychedelic ethics, law, and social policy.
Based within the Oxford-NUS Centre for Neuroethics and Society, the programme is directed by Oxford’s Brian D. Earp, with associate director David B. Yaden (Johns Hopkins) and in collaboration with I. Glenn Cohen (Harvard), and Holly Fernandez Lynch (Penn). The senior advisory directors are Professors Ilina Singh (Oxford), Neil Levy (Oxford), and Julian Savulescu (National University of Singapore).
Background
Psychedelics including psilocybin are being examined in scientific research for their potential clinical efficacy in treating mood and substance use disorders with approval for clinical use looking highly likely. Additionally, policies regulating psychedelic use are changing rapidly across the world, with several US jurisdictions easing criminal restrictions, and at least one state passing measures to permit administration of psilocybin in advance of federal rescheduling.
A number of clinical trials have established the profound––sometimes transformative––impact that psychedelic experiences can have on some people, and yet there are risks as well. These risks do not only operate at the level of the individual, but also at social-historical and political levels. The lack of appropriate ethical, social, legal and policy guidance was a major part of what caused the 1960s-era movement around psychedelics to fail, driving these substances underground, not only exacerbating otherwise manageable harms, but limiting their potential positive impact.
The current drive to conduct more rigorous science on psychedelics, though laudable, can only ever be part of the solution. Just as leading neuroscientists and other researchers are doing their part to guide the development of this crucial moment, leading ethicists, philosophers, and law and policy experts need to be involved at the ground floor.
Project Aims
-
Serving as an international academic and policy hub, bringing together leading researchers and other stakeholders throughout society to advance critically engaged and reflexive integration of psychedelic science with ethics, law, and policy.
-
Ethics-to-public policy pipeline, building practical working links with on-the-ground regulators, lawmakers, practitioners.
-
Foundational academic articles on psychedelic ethics, advancing to the bioethics community the notion of psychedelic ethics as a branch of medical- and bioethics of substantive importance and conceptual novelty.
-
Training the next generation of leaders in psychedelic ethics and policy through postdoctoral positions and PhD studentships, with opportunities to visit, collaborate with, and learn from cutting-edge work in psychedelic science and law at partner institutions.
-
Hosting an inaugural, then annual, global summit on psychedelic ethics, gathering together key figures from multiple sectors to produce up-to-date consensus statements outlining indispensable ethical, legal, and policy guardrails needed to safeguard the development of the psychedelic ecosystem – both medical and non-medical – and provide expert guidance to researchers, practitioners, industry.
-
Ongoing policy briefs to governments and non-profits to help guide the development of ethical and effective regulatory structures.
-
Public attitudes surveys and robust social science research tracking and understanding public responses to (and readiness for) novel uses of, and access to, psychedelics.
-
Responsible communication of psychedelic science and ethics through press releases, engagement with media partners, blog posts, podcasts, video explainers, and other multimedia approaches.
Inaugural HOPE Summit on Psychedelic Ethics
The HOPE Programme's Inaugural Summit took place in August 2023 at the University of Oxford, with Keynote lectures from Yuria Celidwen and Paul Appelbaum.
More information below.
|
Programme DirectorBrian D. Earp, PhD, MSc, MPhil, is a leading neuroethicist based at Oxford with more than 10 years of research experience in psychedelic ethics. Brian is Co-Director of the Oxford Experimental Bioethics Lab, and Associate Director of the Yale-Hastings Program in Ethics and Health Policy, Yale University and The Hastings Center. Brian is also an Associate Editor of the leading Journal of Medical Ethics, published by the British Medical Journal (BMJ). Brian holds a PhD from Yale University in philosophy and psychology, an MSc from Oxford in experimental psychology, and an MPhil from Cambridge University in the history, philosophy, and sociology of science, technology, and medicine. Brian is co-author of Love Drugs: The Chemical Future of Relationships (Stanford University Press, 2020), the first mainstream book for a general audience focused on the ethics of psychedelic-assisted couples counseling, both at the individual and societal levels. |
|
Associate DirectorDavid B. Yaden, PhD, is the Roland R. Griffiths Professor of Psychedelic Research at Johns Hopkins University School of Medicine. His research interests include characterizing the acute subjective effects of psychedelics, investigating their capacity to impact well-being and worldview, as well as testing their treatment potential. He is leading a clinical trial on psilocybin and has published on ethical issues of psychedelics in venues such as JAMA. He is co-author of the book, The Varieties of Spiritual Experience with Oxford University Press. |
|
Lead CollaboratorHolly Fernandez Lynch, JD, MBE, is Assistant Professor of Medical Ethics and Law at the University of Pennsylvania. She pursues conceptual and empirical scholarship regarding clinical research ethics and regulation, access to investigational medicines outside clinical trials, and FDA pharmaceutical policy, especially early approval standards for diseases with unmet treatment needs. She is founder and co-chair of the Consortium to Advance Effective Research Ethics Oversight (www.AEREO.org), a collaborative effort to define, evaluate, and improve the quality and effectiveness of institutional review boards and human research protection programs. Her interests in psychedelics center on ethical research practices, research oversight, and models of access. |
|
Lead CollaboratorI. Glenn Cohen, JD, is James A. Attwood and Leslie Williams Professor of Law, Deputy Dean of the Harvard Law School, and Faculty Director of the Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics. Professor Cohen is one of the world’s leading experts on the intersection of bioethics and the law, having written more than 200 articles and authored, edited, or co-edited more than 18 books on these topics. Cohen has published articles on the legal, ethical, and social policy implications of psychedelics in leading journals including Nature Medicine, Science, and Harvard Law Review. He also founded POPLAR (Project on Psychedelics Law and Regulation) the world’s first academic program focused on law and regulatory policy around psychedelics. |
Senior Advisory Directors
Ilina Singh
Professor of Neuroscience & Society; Neuroscience, Ethics and Society (NEUROSEC) Lead; Co-Director of the Wellcome Trust Centre for Ethics and the Humanities (WEH); Distinguished Research Fellow: Oxford Uehiro Centre
Professor Ilina Singh's research focusses on the social and ethical dimensions of research and innovation in neuroscience and psychiatry.
Neil Levy
Professor of Philosophy at Macquarie University, Sydney and a Senior Research Fellow at the Uehiro Centre for Practical Ethics, University of Oxford.
Professor Neil Levy works principally at the intersection of philosophy of mind and psychology and ethics. He specializes in empirical approaches to ethics and social issues
Julian Savulescu
Chen Su Lan Centennial Professor in Medical Ethics at the National University of Singapore, Director of the Centre for Biomedical Ethics (CBME), Co-Director of the Wellcome Trust Centre for Ethics and the Humanities (WEH)
Professor Julian Savulescu is recognised internationally for his world-leading research into the ethics of future technologies. He held the Uehiro Chair in Practical Ethics at the University of Oxford between 2002 and 2022.
